Skip to main content

Research Repository

Advanced Search

All Outputs (147)

Speaking of the (Barely legal) elephant in the room: Herbal or dietary supplement related acute liver failure (2021)
Journal Article
Aithal, G. P. (2022). Speaking of the (Barely legal) elephant in the room: Herbal or dietary supplement related acute liver failure. Liver Transplantation, 28(2), 159-160. https://doi.org/10.1002/lt.26377

Titled ‘Barely legal’, Banksy’s first United States (USA) exhibition showcased Tai, an Indian elephant, painted with pink and gold pattern to blend in with the wallpaper of the living room, intended to mock the art world’s claim for the true portraya... Read More about Speaking of the (Barely legal) elephant in the room: Herbal or dietary supplement related acute liver failure.

Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease (2021)
Journal Article
Mak, A. L., Lee, J., van Dijk, A., Vali, Y., Aithal, G. P., Schattenberg, J. M., …Holleboom, A. G. (2021). Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines, 9(12), Article 1920. https://doi.org/10.3390/biomedicines9121920

The prevalence and severity of non-alcoholic fatty liver disease (NAFLD) is increasing, yet adequately validated tests for care paths are limited and non-invasive markers of disease progression are urgently needed. The aim of this work was to summari... Read More about Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.

Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study (2021)
Journal Article
Hashim, A., Bremner, S., Grove, J., Astbury, S., Mengozzi, M., O’Sullivan, M., …Verma, S. (2022). Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study. Liver International, 42(3), 628-639. https://doi.org/10.1111/liv.15122

Background/aims: Community-based assessment and management of chronic liver disease (CLD) in people who are homeless (PWAH) remains poorly described. We aimed to determine prevalence/predictors of chronic liver disease (CLD) in PWAH and assess perfor... Read More about Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study.

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance (2021)
Journal Article
Johnson, K., Leary, P. J., Govaere, O., Barter, M. J., Charlton, S. H., Cockell, S. J., …Twiss, J. (2022). Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports, 4(2), Article 100409. https://doi.org/10.1016/j.jhepr.2021.100409

Background & Aims: Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages. Methods: We profiled 2,083 s... Read More about Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.

Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Taal, M. W., Aithal, G. P., Zhang, W., …Abhishek, A. (2022). Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. Rheumatology, 61(7), 2783-2791. https://doi.org/10.1093/rheumatology/keab790

OBJECTIVE: To develop and validate a prognostic model for LEF discontinuation with abnormal blood test results. METHODS: Data from the Clinical Practice Research Datalink Gold and Aurum were used for model development and external validation, respect... Read More about Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.

A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers (2021)
Journal Article
Whitfield, J. B., Schwantes-An, T. H., Darlay, R., Aithal, G. P., Atkinson, S. R., Bataller, R., …Seth, D. (2022). A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of Hepatology, 76(2), 275-282. https://doi.org/10.1016/j.jhep.2021.10.005

Background & Aims: Only a minority of excess alcohol drinkers develop cirrhosis. We developed and evaluated risk stratification scores to identify those at highest risk. Methods: Three cohorts (GenomALC-1: n = 1,690, GenomALC-2: n = 3,037, UK Biobank... Read More about A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.

Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): A study protocol of an efficacy mechanism evaluation (2021)
Journal Article
Al-Awadi, A., Grove, J., Taylor, M., Valdes, A., Vijay, A., Bawden, S., …Aithal, G. (2021). Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): A study protocol of an efficacy mechanism evaluation. BMJ Open, 11(10), Article e045802. https://doi.org/10.1136/bmjopen-2020-045802

Introduction A Low Glycaemic Index (LGI) diet is a proposed lifestyle intervention in non-alcoholic fatty liver diseases (NAFLD) which is designed to reduce circulating blood glucose levels, hepatic glucose influx, insulin resistance and de novo lipo... Read More about Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): A study protocol of an efficacy mechanism evaluation.

The role of hepatic lipid composition in obesity-related metabolic disease (2021)
Journal Article
Willis, S. A., Bawden, S., Malaikah, S., Sargeant, J. A., Stensel, D. J., Aithal, G. P., & King, J. A. (2021). The role of hepatic lipid composition in obesity-related metabolic disease. Liver International, 41(12), 2819-2835. https://doi.org/10.1111/liv.15059

Obesity is a primary antecedent to non-alcoholic fatty liver disease whose cardinal feature is excessive hepatic lipid accumulation. Although total hepatic lipid content closely associates with hepatic and systemic metabolic dysfunction, accumulating... Read More about The role of hepatic lipid composition in obesity-related metabolic disease.

The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study (2021)
Journal Article
Subhani, M., Sheth, A., Unitt, S., Aithal, G. P., Ryder, S. D., & Morling, J. R. (2022). The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study. Alcohol and Alcoholism, 57(2), 203-210. https://doi.org/10.1093/alcalc/agab059

Aim: To assess the impact of Covid-19 on alcohol use disorders (AUD) and the role of universal alcohol screening (UAS) in an inpatient setting. Methods: Retrospective cohorts were defined as pre-pandemic and pandemic admitted to Nottingham University... Read More about The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study.

Estimating the clinical prevalence of Wilson’s disease in the UK (2021)
Journal Article
Wijayasiri, P., Hayre, J., Nicholson, E. S., Kaye, P., Wilkes, E. A., Evans, J., …Aravinthan, A. D. (2021). Estimating the clinical prevalence of Wilson’s disease in the UK. JHEP Reports, 3(5), Article 100329. https://doi.org/10.1016/j.jhepr.2021.100329

Background and Aim
The clinical prevalence of Wilson’s disease (WD) in the UK remains unknown. The estimated genetic prevalence in the UK, 142/million, is higher than the clinical prevalence (15/million) reported in other European studies. The aim o... Read More about Estimating the clinical prevalence of Wilson’s disease in the UK.

Advanced preclinical models for evaluation of drug induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [Pro-Euro-DILI-Net] (2021)
Journal Article
Fernandez-Checa, J. C., Bagnaninchi, P., Ye, H., Sancho-Bru, P., Falcon-Perez, J. M., Royo, F., …Nelson, L. J. (2021). Advanced preclinical models for evaluation of drug induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [Pro-Euro-DILI-Net]. Journal of Hepatology, 75(4), 935-959. https://doi.org/10.1016/j.jhep.2021.06.021

Drug induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. Given the wide use of both prescribed and over the counter drugs, DILI has become a majo... Read More about Advanced preclinical models for evaluation of drug induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [Pro-Euro-DILI-Net].

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis (2021)
Journal Article
Erhardtsen, E., Rasmussen, D. G., Frederiksen, P., Leeming, D. J., Shevell, D., Gluud, L. L., …Schattenberg, J. M. (2021). Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis. JHEP Reports, 3(4), Article 100317. https://doi.org/10.1016/j.jhepr.2021.100317

Background & Aims
Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver bio... Read More about Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis.

Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI (2021)
Journal Article
Ashby, K., Zhuang, W., González-Jimenez, A., Alvarez-Alvarez, I., Lucena, M. I., Andrade, R. J., …Chen, M. (2021). Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. Journal of Hepatology, 75(2), 333-341. https://doi.org/10.1016/j.jhep.2021.03.021

Background & Aims
Although most drug-induced liver injury (DILI) cases resolve after the culprit medication is discontinued, time to recovery varies among patients, with 6-12% developing a chronic disease. Here, we investigated clinical factors and... Read More about Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.

Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH) (2021)
Journal Article
Gordon, V. M., Adhikary, R., Aithal, G. P., Appleby, V., Das, D., Day, J., …Gleeson, D. (2022). Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH). Frontline Gastroenterology, 13(2), 126-132. https://doi.org/10.1136/flgastro-2020-101661

Background Autoimmune hepatitis (AIH) is a substantial UK health burden, but there is variation in care, facilities and in opinion regarding management. We conducted an audit of service provision and care of patients with AIH in 28 UK hospitals. Meth... Read More about Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH).

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis (2021)
Journal Article
Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N., Trauner, M., Boursier, J., …Pavlides, M. (2021). Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, https://doi.org/10.1136/gutjnl-2021-324243

Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled... Read More about Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis (2021)
Journal Article
Mózes, F. E., Levick, C. K., Vali, Y., Palaniyappan, N., Liu, C.-H., Zafarmand, M. H., …Pavlides, M. (2021). Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. Journal of Hepatology, 75(4), 770-785. https://doi.org/10.1016/j.jhep.2021.04.044

Background and Aims: Vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), two-dimensional shear wave elastography (2DSWE), magnetic resonance elastography (MRE), and magnetic resonance imaging (MRI) are proposed a... Read More about Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis.

Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients (2021)
Journal Article
Hu, T., Hu, Y., Wang, G., Zhu, Y., Aithal, G. P., Cai, T., …Jiang, F. (2021). Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. Liver International, 41(7), 1565-1575. https://doi.org/10.1111/liv.14896

Background and Aims: Anti-tuberculosis drugs remain as an important cause of drug-induced liver injury (DILI) worldwide. Adverse drug reactions reduce the effectiveness of treatment. We aimed to determine the incidence and risk factors associated wit... Read More about Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients.

Longitudinal assessment of symptoms and risk of SARS-CoV-2 infection in healthcare workers across 5 hospitals to understand ethnic differences in infection risk. (2021)
Journal Article
Valdes, A. M., Moon, J. C., Vijay, A., Chaturvedi, N., Norrish, A., Ikram, A., …Manisty, C. (2021). Longitudinal assessment of symptoms and risk of SARS-CoV-2 infection in healthcare workers across 5 hospitals to understand ethnic differences in infection risk. eClinicalMedicine, 34, 1-8. https://doi.org/10.1016/j.eclinm.2021.100835

Background:: Healthcare workers (HCWs) have increased rates of SARS-CoV-2 infection compared with the general population. We aimed to understand ethnic differences in SARS-CoV-2 seropositivity among hospital healthcare workers depending on their hosp... Read More about Longitudinal assessment of symptoms and risk of SARS-CoV-2 infection in healthcare workers across 5 hospitals to understand ethnic differences in infection risk..

Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial (2021)
Journal Article
Mingrone, G., Baar, A. C. V., Devière, J., Hopkins, D., Moura, E. G. D., Cercato, C., …Bergman, J. J. (2022). Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut, 71(2), 254-264. https://doi.org/10.1136/gutjnl-2020-323608

Objective: Hydrothermal duodenal mucosal resurfacing (DMR) is a safe, outpatient endoscopic procedure. REVITA-2, a double-blind, superiority RCT, investigates safety and efficacy of DMR using the single catheter Revita system (Revita DMR [catheter an... Read More about Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial.